COLOMBO, November 14, 2026 – Sri Lanka is investing millions of dollars in domestic pharmaceutical manufacturing to reduce its dependence on imported medicines, but the construction of new factories alone may not deliver the foreign exchange savings promised. With medical and pharmaceutical imports reaching US$667 million in 2025, the real test will be whether local production reduces costs, meets international quality standards and delivers affordable medicines to patients.
The planned completion of the Synergy Pharmaceuticals manufacturing complex at the Bingiriya Investment Zone represents an important step towards expanding Sri Lanka’s domestic pharmaceutical industry.
Built with an investment of approximately US$16 million, the facility is described as the country’s largest Western pharmaceutical manufacturing plant and is expected to meet up to 25% of domestic pharmaceutical requirements while producing medicines for export markets.
Deputy Minister of Health Dr. Hansaka Wijemuni recently inspected the premises to assess construction progress, machinery installation and the development of its advanced Research and Development (R&D) laboratory.
The factory is expected to manufacture tablets, capsules, injectable medicines, hormonal medications and cancer treatment drugs.
During the inspection, Wijemuni pledged government assistance to expedite the remaining work and begin commercial production.
Although the investment could improve Sri Lanka’s pharmaceutical manufacturing capacity, economic analysts caution that expanding local production does not automatically eliminate import dependence or guarantee lower medicine prices.
Sri Lanka’s US$667 Million Pharmaceutical Import Bill
Sri Lanka recorded approximately US$667 million in imports under the medical and pharmaceutical products category in 2025.
The figure illustrates the country’s substantial dependence on foreign suppliers for medicines and related medical products.
For an economy recovering from a severe foreign exchange crisis, reducing unnecessary import expenditure remains an important economic priority.
Sri Lanka currently relies on overseas manufacturers for most registered pharmaceutical products.
A 2026 academic study examining pharmaceutical registration between 1991 and 2025 found that locally manufactured products accounted for only 13.4% of registered medicines in 2025.
Imported products represented the remaining 86.6%.
The same study found that locally manufactured products accounted for just 2.8% of registrations in 2009, indicating that domestic pharmaceutical manufacturing has expanded considerably over the intervening period.
Nevertheless, the industry remains heavily dependent on imports.
These figures describe the proportion of registered pharmaceutical products by country of manufacture, rather than the percentage of medicines consumed, the volume supplied to hospitals or the value of national pharmaceutical expenditure.
Understanding that distinction is essential when evaluating claims about the industry’s capacity to meet domestic demand.
Three Economic Questions Behind Local Pharmaceutical Manufacturing
The government’s programme to encourage pharmaceutical manufacturing offers potential benefits, including increased investment, employment, technical expertise and improved medicine availability.
However, three important issues must be considered before concluding that new factories will substantially reduce Sri Lanka’s foreign exchange requirements.
1. Why Might Local Manufacturing Fail to Save the Expected Dollars?
Producing tablets, capsules or injectable medicines in Sri Lanka does not necessarily mean that every component used in their manufacture is produced locally.
Many pharmaceutical manufacturers depend on imported Active Pharmaceutical Ingredients (APIs), excipients, specialised materials and production equipment.
APIs are the substances responsible for the therapeutic effects of medicines.
Even when the final medicine is manufactured and packaged in Sri Lanka, importing these ingredients requires foreign exchange.
Consequently, some expenditure previously directed towards importing finished medicines may instead be spent on importing the materials needed to produce them domestically.
This does not mean local manufacturing generates no foreign exchange savings.
The economic benefit depends on the value of imported inputs compared with the cost of importing equivalent finished pharmaceutical products.
Domestic production can also create employment, develop technical expertise, improve supply reliability and generate export earnings.
However, those benefits must be measured against production costs, imported components and any financial incentives granted to manufacturers.
A factory that assembles or formulates medicines using imported ingredients may still reduce the overall import bill, but the savings could be substantially smaller than the value of the finished medicines it replaces.
The crucial measure is therefore the net foreign exchange benefit rather than the gross value of pharmaceutical products manufactured locally.
2. Why Do Pharmaceutical Factories Take So Long to Begin Production?
Several pharmaceutical manufacturing projects in Sri Lanka illustrate the time required to move from investment approval to commercial production.
The Synergy Pharmaceuticals project at Bingiriya reportedly received approval in 2019, with development beginning in 2020.
Six years later, the facility is approaching its final construction and commissioning stages.
Other projects are also progressing towards production.
The Koggala insulin manufacturing project, involving expenditure reported to exceed Rs. 3 billion, is expected to begin production in 2027.
Meanwhile, the Sunshine Healthcare–Zydus pharmaceutical manufacturing project at the Horana Investment Zone involves an investment commitment of approximately US$20 million, with operations targeted for 2028.
Such projects require more than the construction of factory buildings.
Pharmaceutical manufacturing facilities must install specialised equipment, establish controlled production environments, develop quality assurance systems and comply with applicable regulatory requirements.
Products must also meet standards governing safety, efficacy and manufacturing quality before they can be supplied commercially.
These requirements help explain why pharmaceutical investments can involve extended development periods, although the specific reasons for delays at individual facilities require examination of their project records.
The economic return on these investments will depend on how efficiently the factories move into production, obtain regulatory approvals and supply medicines consistently.
3. Could Local Pharmaceutical Manufacturing Become a Financial Disadvantage?
Domestic manufacturing can strengthen medicine security, but preferential treatment for local producers also carries potential risks.
The Koggala insulin project reportedly operates under a 15-year supply agreement involving the State Pharmaceutical Manufacturing Corporation.
Such long-term purchasing arrangements may provide manufacturers with the financial certainty needed to justify major capital investments.
They can also create concerns if supply agreements reduce competition or commit public institutions to purchasing medicines at prices that are no longer competitive.
Independent observers have therefore called for transparency in procurement arrangements, government purchasing commitments and tax concessions provided to pharmaceutical manufacturers.
The objective should be to support domestic manufacturing without creating protected markets in which patients and public hospitals are required to pay unnecessarily high prices.
Long-term supply agreements are not inherently harmful. Their value depends on the pricing arrangements, quality requirements, delivery obligations and safeguards protecting the public interest.
Similarly, tax incentives may help establish new manufacturing capacity, but the benefits should be assessed against the revenue surrendered by the government.
A domestic pharmaceutical industry that depends permanently on expensive protection could undermine the very economic savings it is intended to achieve.
National Pharmaceutical Policy Must Deliver Measurable Results
Sri Lanka’s National Medicinal Drug Policy for 2026–2030 provides an opportunity to establish clearer standards for evaluating the industry’s performance.
Approved by the Cabinet in August 2026, the policy prioritises access to safe, effective and affordable essential medicines while encouraging efficient domestic pharmaceutical production.
Its implementation should be assessed against measurable objectives covering local manufacturing, the development of raw material capabilities, scientific research, supply reliability and export performance.
The National Medicines Regulatory Authority (NMRA) also has an important role in ensuring that locally manufactured medicines meet the applicable standards of safety, quality and efficacy.
Domestic manufacturers should not receive weaker regulatory scrutiny simply because their products are manufactured in Sri Lanka.
Equally, local production should be evaluated against its ability to supply medicines consistently and competitively.
The success of pharmaceutical investment will ultimately depend on whether the country develops a reliable industry that reduces net foreign exchange expenditure while improving access to affordable medicines.
Opening a new factory may demonstrate industrial progress, but it does not establish pharmaceutical self-sufficiency.
Sri Lanka must avoid replacing dependence on expensive imported medicines with dependence on equally expensive domestic products protected from competition.
The real achievement will come when investment in local manufacturing produces measurable foreign exchange savings, maintains internationally acceptable quality and allows patients to obtain the medicines they need at prices they can afford.
